Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how the gut microbiome and serum metabolome differ between people with lactose intolerance (LI) and those without it. The researchers combined a paired-sample analysis of American Gut Project (AGP) data with metagenomic and untargeted metabolomic analyses in a separate cohort. They also performed fecal microbiota transplantation (FMT) experiments to test whether the LI-associated gut microbiome could influence inflammatory outcomes. The goal was to characterize the interaction between gut microbiota and circulating metabolites in LI.
Who was studied?
The study drew on two data sources: paired samples from the American Gut Project (AGP), a large public microbiome dataset, and a Chinese cohort in which metagenomic and metabolomic profiling was performed. The abstract does not give exact sample sizes for either group. FMT experiments were also conducted, implying an animal model component, though further details are not specified in the abstract.
What were the most important findings?
Fourteen microbial genera differed significantly between LI and control individuals in the AGP data. In the Chinese cohort, a machine learning approach identified seven bacterial species and nine metabolites that could distinguish the two groups. Notably, increased Escherichia coli in the LI group was negatively correlated with several metabolites, including PC (22:6/0:0), indole, and Lyso PC, while reduced levels of Faecalibacterium prausnitzii and Eubacterium rectale were positively associated with other metabolic changes.
What are the greatest implications of this study?
The findings suggest that lactose intolerance is accompanied by a distinct gut microbial and metabolic signature, not just a lactase enzyme deficiency. The rise in Escherichia coli alongside depletion of beneficial short-chain-fatty-acid producers like Faecalibacterium prausnitzii and Eubacterium rectale points to a shift toward a more pro-inflammatory microbial community. This raises the possibility that microbiome-targeted interventions could help manage LI-related gastrointestinal symptoms, and the FMT experiments support a causal link between this altered microbiome and inflammatory outcomes.